Search RGBPP
Regen BioPharma Inc
OTC, OTC · CIK 1589150
Last close0
Daily change-0.00 (-0.00%)
10 Years gain-99.99%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
RGBPP · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0930
Fundamental
60.5Momentum
0.0Acceleration
0.0Confidence
79.0Annual Revenue12
Quarterly Revenue40
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.1 / 25
Quality16.6 / 25
Capital Efficiency20.0 / 20
Balance Sheet8.7 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 149.8071 percentage points.
Heavy share dilution · HIGHDiluted share count increased 2755.7834%.
Key Metrics
Revenue Growth TTM-0.13%OK
Revenue CAGR 3Y23.52%OK
Gross Margin100%OK
Operating Margin-305.41%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-22.13%OK
Net Debt / CFO0xOK
Diluted Share Growth 1Y2,755.78%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Sep 30, 2025 | $236,561.00 | $236,561.00 | -$338,540.00 | -$383,591.00 | n/a | 100% | -143.11% | n/a | n/a | 23.52M |
| 2025 FY Sep 30, 2024 | $236,560.00 | $236,560.00 | -$417,221.00 | -$751,536.00 | n/a | 100% | -176.37% | n/a | n/a | 4.11M |
| 2024 FY Sep 30, 2023 | $236,560.00 | $236,559.00 | -$686,950.00 | -$173,917.00 | n/a | 100% | -290.39% | n/a | n/a | 3.54M |
| 2023 FY Sep 30, 2022 | $125,517.00 | n/a | -$339,605.00 | -$606,921.00 | n/a | n/a | -270.56% | n/a | n/a | 3.14M |
| 2022 FY Sep 30, 2021 | $61,194.00 | n/a | -$200,771.00 | -$1.13M | n/a | n/a | -328.09% | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $236,260.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-038576, 0001493152-26-006526 |
| Revenue Growth TTM | -0.13% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-038576, 0001493152-26-006526 |
| Revenue CAGR 3Y | 23.52% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-25-029526 |
| Revenue CAGR 5Y | 16.55% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001493152-25-029526 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001493152-25-029526 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-038576, 0001493152-26-006526 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001493152-26-038576, 0001493152-26-006526 |
| Operating Margin | -305.41% | Operating Income / Revenue | OK | 0001493152-26-038576, 0001493152-26-006526 |
| Net Debt / CFO | 0x | Net Debt / CFO | OK | 0001493152-26-038576, 0001493152-26-022924 |
| Current Ratio | 0.05x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001493152-26-038576, 0001493152-26-006526 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | derived |